# Avalyn Pharma Inc. (AVLN)

Source: https://www.quantisnow.com/company/AVLN
Generated: 2026-11-14T04:06:22.092Z

- Ticker: AVLN
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2026
- SEC CIK: 0001540171
- Website: https://www.avalynpharma.com/

## About

Avalyn aims to transform the treatment paradigm for pulmonary fibrosis and other serious, rare respiratory diseases. The company is advancing optimized inhaled formulations of established antifibrotic medicines designed to deliver drug directly to the lungs, enhance local efficacy, and reduce systemic side effects. Avalyn's AP01 program is an optimized inhaled formulation of pirfenidone currently being evaluated in MIST, a global Phase 2b clinical trial in patients with progressive pulmonary fibrosis (PPF). AP01 has indicated encouraging safety and clinical activity across Phase 1b and multi-year open-label extension trials, with long-term data supporting the potential to preserve lung function while improving tolerability relative to historical oral pirfenidone. Avalyn's AP02 program is an optimized inhaled formulation of nintedanib currently being evaluated in AURA, a global Phase 2 clinical trial in patients with idiopathic pulmonary fibrosis (IPF).

## Latest AVLN news and filings

- 2026-11-12 16:35 UTC [SEC Form 4] [See Remark 1 Fmr Llc sold $6,701,004 worth of shares (228,454 units at $29.33) (SEC Form 4)](https://www.quantisnow.com/insight/see-remark-1-fmr-llc-sold-6701004-worth-of-shares-6787193)
- 2026-11-12 13:15 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Avalyn Pharma Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-avalyn-pharma-inc-6786580)
- 2026-11-12 13:08 UTC [SEC Form 8-K] [Avalyn Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/avalyn-pharma-inc-filed-sec-form-8-k-results-of-operations-6786546)
- 2026-11-12 13:00 UTC [Earnings] [Avalyn Reports Third Quarter 2026 Financial Results and Recent Business Highlights](https://www.quantisnow.com/insight/avalyn-reports-third-quarter-2026-financial-results-and-recent-business-6786453)
- 2026-11-03 13:00 UTC [Conference Announcement] [Avalyn to Present at Upcoming Investor Conferences](https://www.quantisnow.com/insight/avalyn-to-present-at-upcoming-investor-conferences-6768451)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/AVLN
- Earnings history: https://www.quantisnow.com/earnings/AVLN
- Dividend history: https://www.quantisnow.com/dividends/AVLN
- Insider transactions: https://www.quantisnow.com/insiders/AVLN
- Options chain: https://www.quantisnow.com/options/AVLN
- SEC 8-K filings only: https://www.quantisnow.com/company/AVLN/8-k
- RSS and alerts for AVLN: https://www.quantisnow.com/docs/rss-feeds.md